Inductive Beacon Ranks 1st in OpenADMET CYP Inhibition Prediction, Surpassing NVIDIA
1st Place in 750-Compound Blind Evaluation
Inductive Bio's Beacon model took 1st place among 271 participating teams in the OpenADMET CYP direct inhibition blind challenge. Participants predicted the pIC50 values, representing inhibition potency, for CYP3A4, CYP2D6, CYP2C9, and CYP1A2 across 750 compounds with masked measurements prior to the end of the test. NVIDIA ranked 3rd and Recursion Pharmaceuticals ranked 4th, signifying that this result was a comparison under identical conditions against external competing models rather than simple internal validation.
Data Competitiveness Demonstrated by Four Consecutive Wins
Inductive has consecutively won the 2025 ASAP-Polaris-OpenADMET antiviral challenge and the 2026 ExpansionRx, PXR, and CYP challenges. By leading across four competitions against 19 drug discovery benchmarks and over 1,000 competing submissions, it has strengthened the evidence for a repeatable prediction framework rather than one-off model tuning. The company highlights its core competitiveness in two areas: a consortium that integrates ADMET (Absorption, Distribution, Metabolism, Excretion, and Toxicity) data from multiple partners, and client-specific fine-tuning of chemical space.
Performance as a Candidate Screening Tool, Not a Clinical Asset
This result represents the validation of a discovery-stage platform for screening small-molecule candidates prior to clinical entry, rather than efficacy data for specific brand/generic drugs or clinical Phase 1, 2, or 3 assets. CYP inhibition can increase the exposure of co-administered drugs, leading to drug-drug interactions (DDI), and the FDA's ICH M12 guideline treats CYP-based testing as a key evaluation in the development process. Therefore, while higher prediction accuracy can reduce design cycles by removing risky compounds before synthesis and experimentation, this should not be interpreted as direct proof of a candidate's clinical success or regulatory approval.
Commercialization is the Next Hurdle in a $2.9 Billion Market
The global AI drug discovery market is projected to expand from $2.9 billion in 2026 to $13.8 billion by 2033, with competition centered on Inductive's Beacon and Indy, NVIDIA's BioNeMo, and Recursion's Recursion OS. Recursion is raising the standard for clinical translation capabilities by developing the MEK1/2 inhibitor REC-4881 in Phase 2 clinical trials, in addition to its platform. While Inductive's No. 1 ranking is advantageous for customer acquisition and expanding data consortiums, sustained growth in enterprise value hinges on the expansion of pharmaceutical contracts and the quantitative disclosure of reductions in development candidate lead times and experimental costs.
Ranking first among 271 teams and 750 blind compounds is a signal that Inductive Bios has secured the technical credibility to compete with NVIDIA's BioNeMo and Recursion's OS in the $2.9 billion AI drug discovery market by 2026. For researchers, it means the ability to filter out CYP3A4, 2D6, 2C9, and 1A2 inhibition risks before synthesis, reducing the number of iterations for drug-drug interaction assessment and candidate optimization. However, Beacon is a discovery/preclinical stage tool, and unlike Recursion, which possesses the Phase 2 MEK1/2 inhibitor REC-4881, this announcement does not include clinical efficacy or FDA-approved assets. In the short term, this is positive for pharmaceutical company adoption and data consortium expansion; long-term value will be determined by whether the speed of candidate selection and cost savings translate into contract revenue.